Countries in South and Central America are famous for medical tourism, but they have seen adverse effects of the COVID-19 pandemic in the past two years. After the onset of the second wave of the COVID-19 outbreak, there were 5,395,044 new cases in Argentina. Thus, the region was on the verge of imposing the second lockdown in 2021. In 2020, the market stakeholders lost their businesses due to the shutdown of their businesses for indefinite periods. SARS-2-CoV can contribute to VTE or arterial disease due to increased inflammatory response, hypoxia, immobilization, and DIC. The risk of developing VTE is higher in critically ill COVID-19 patients. In addition to hemostatic changes, immobility, systemic inflammatory status, mechanical ventilation, and central catheters increase the risk of thromboembolism, while diet-related and hepatic changes alter the production of coagulation factors. Identified risk factors for VTE include hospitalization in the intensive care unit, and higher white blood cell count, neutrophil/lymphocyte ratio, and D-dimer value. The COVID-19 pandemic can affect the prevention and treatment of thrombotic or thromboembolic diseases in different ways. The protocols for thromboprophylaxis, anticoagulation, and additional considerations for the management of coagulation disorders and the bleeding should be implemented in each facility by the most current recommendations in the region.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 202.69 Million |
| Market Size by 2028 | US$ 303.39 Million |
| CAGR (2021 - 2028) | 5.9% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Product Type
|
| Regions and Countries Covered |
South and Central America
|
| Market leaders and key company profiles |
|
The South and Central America Low Molecular Weight Heparin Market is valued at US$ 202.69 Million in 2021, it is projected to reach US$ 303.39 Million by 2028.
As per our report South and Central America Low Molecular Weight Heparin Market, the market size is valued at US$ 202.69 Million in 2021, projecting it to reach US$ 303.39 Million by 2028. This translates to a CAGR of approximately 5.9% during the forecast period.
The South and Central America Low Molecular Weight Heparin Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South and Central America Low Molecular Weight Heparin Market report:
The South and Central America Low Molecular Weight Heparin Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South and Central America Low Molecular Weight Heparin Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South and Central America Low Molecular Weight Heparin Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For South and Central America Low Molecular Weight Heparin Market
